share_log

和黃醫藥：自願性公告－和黃醫藥將於美國癌症研究協會（AACR）2024年年會公佈數據

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Data to be Presented at AACR Congress 2024

香港交易所 ·  Apr 5 04:33
Summary by Moomoo AI
和黃醫藥（HUTCHMED）將於2024年4月5日至10日在美國加利福尼亞州聖地亞哥舉行的美國癌症研究協會年會上，公佈其自主研發的多個化合物的最新研究數據。其中包括menin-MLL抑制劑HMPL-506的初步臨床前數據，該化合物用於治療特定類型的急性白血病，並展示出與其他藥物聯用時的協同抗腫瘤作用。另一項研究為新型CD38靶向抗體偶聯藥物HMPL-A067的初步臨床前數據，其在多個B細胞惡性腫瘤模型中顯示出優於現有治療的抗腫瘤活性。和黃醫藥還將公佈其他在研藥物的臨床前數據，包括ERK 1/2抑制劑HMPL-295、Syk抑制劑索樂匹尼布、VEGFR抑制劑呋喹替尼和MET抑制劑賽沃替尼等。這些數據將有助於和黃醫藥進一步開發和商業化其靶向藥物和免疫療法，以治療癌症和免疫性疾病。
和黃醫藥（HUTCHMED）將於2024年4月5日至10日在美國加利福尼亞州聖地亞哥舉行的美國癌症研究協會年會上，公佈其自主研發的多個化合物的最新研究數據。其中包括menin-MLL抑制劑HMPL-506的初步臨床前數據，該化合物用於治療特定類型的急性白血病，並展示出與其他藥物聯用時的協同抗腫瘤作用。另一項研究為新型CD38靶向抗體偶聯藥物HMPL-A067的初步臨床前數據，其在多個B細胞惡性腫瘤模型中顯示出優於現有治療的抗腫瘤活性。和黃醫藥還將公佈其他在研藥物的臨床前數據，包括ERK 1/2抑制劑HMPL-295、Syk抑制劑索樂匹尼布、VEGFR抑制劑呋喹替尼和MET抑制劑賽沃替尼等。這些數據將有助於和黃醫藥進一步開發和商業化其靶向藥物和免疫療法，以治療癌症和免疫性疾病。
HUTCHMED WILL ANNOUNCE THE LATEST RESEARCH DATA ON SEVERAL OF ITS INDEPENDENTLY DEVELOPED COMPOUNDS AT THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH IN SAN DIEGO, CALIFORNIA, USA, FROM APRIL 5 TO 10, 2024. These include preliminary preclinical data for the menin-MLL inhibitor HMPL-506, which is used to treat certain types of acute leukemia and has demonstrated a synergistic antitumor effect when used with other drugs. Another study looked at preliminary pre-clinical data for the novel CD38-targeting antibody doplicular drug HMPL-A067, which showed antitumor activity superior to existing treatments in multiple B-cell malignant tumor models. And Wong Pharmaceuticals will also release pre-clinical data on other investigational drugs, including the ERK 1/2 inhibitor HMPL-295, the Syk inhibitor solepinib, the VEGFR inhibitor furoquintin and the MET inhibitor svotini, among others. These data will help Wong Pharmaceuticals further develop and commercialize its targeted drugs and immunotherapy for the treatment of cancer and immune diseases.
HUTCHMED WILL ANNOUNCE THE LATEST RESEARCH DATA ON SEVERAL OF ITS INDEPENDENTLY DEVELOPED COMPOUNDS AT THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH IN SAN DIEGO, CALIFORNIA, USA, FROM APRIL 5 TO 10, 2024. These include preliminary preclinical data for the menin-MLL inhibitor HMPL-506, which is used to treat certain types of acute leukemia and has demonstrated a synergistic antitumor effect when used with other drugs. Another study looked at preliminary pre-clinical data for the novel CD38-targeting antibody doplicular drug HMPL-A067, which showed antitumor activity superior to existing treatments in multiple B-cell malignant tumor models. And Wong Pharmaceuticals will also release pre-clinical data on other investigational drugs, including the ERK 1/2 inhibitor HMPL-295, the Syk inhibitor solepinib, the VEGFR inhibitor furoquintin and the MET inhibitor svotini, among others. These data will help Wong Pharmaceuticals further develop and commercialize its targeted drugs and immunotherapy for the treatment of cancer and immune diseases.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more